What we do Wockhardt Ltd is a global pharmaceutical and biotechnology company providing affordable, high-quality medicines and specialty hospital services across key international markets. |
Founded in 1,999 |
Market share Leading in innovative pharmaceuticals, biosimilars, and novel antibiotics with 83% revenues from international markets. |
Problem solved Addresses antibiotic resistance with new drug discoveries and provides advanced biosimilar diabetes treatments and hospital care. |
Top clients or who we serve Serves global pharma markets including USA, Europe, India; caters to hospitals, healthcare providers, and patients (B2B and B2C). |
Key management Dr. Habil Khorakiwala, Chairman and Executive Director, recognized innovator and biotech pioneer. |
Our journey and innovations Pioneered recombinant insulin in Asia, acquired global firms, launched novel antibiotics with multiple regulatory approvals, and expanded international manufacturing. |
Where we operate Operations in India, USA, UK, Ireland, Europe, and Middle East with exports worldwide. |
Top products or what we offer Pharmaceuticals, novel antibiotics like Zaynich and Miqnaf, biosimilar insulins, and specialty hospital services. |
Top brands Zaynich (beta-lactam enhancer antibiotic), Miqnaf (respiratory antibiotic), Emrok (antibiotic), Wosulin (insulin), Mypen (insulin delivery device). |
Raw materials needed Active pharmaceutical ingredients and biotechnological raw materials sourced globally. |
Raw materials supplier Supplied by multiple international and Indian API manufacturers. |
Recurring vs cyclical contribution Revenue largely recurring from pharmaceuticals and biosimilars; some cyclicality in hospital services. |
Our industry position Strong global player in anti-infectives and biosimilars with innovation-driven growth and expanding market share. |
Financial highlights FY25 revenue Rs 3,074 Cr with EBITDA Rs 418 Cr; improving profitability and reducing net debt. |
Geographical revenue split India 22%, USA 3%, Europe 50%, Rest of World 23%. |
Order book Not specified in data. |
Whats driving growth Novel antibiotic launches, biosimilar insulin expansion, and international market penetration. |
Our future plans New drug launches, expanding biosimilar pipeline, increasing manufacturing capacity, and clinical trials progression. |
Our green promise Ongoing initiatives in energy savings, water conservation, and environment-focus across operations. |
Our people and values Emphasis on innovation culture, diversity, ethics, and employee development across global teams. |
Key challenges ahead Regulatory compliance, competition, R&D risks, and market access challenges. |
Interesting facts Only company with five anti-bacterial QIDP approvals by US FDA; pioneering recombinant insulin in Asia. |
Risks and strategy Mitigates regulatory risks through quality systems; focuses on R&D and market expansion to sustain growth. |
